AstraZeneca’s Forxiga has been recommended for approval in the European Union to extend the indication for heart failure with reduced ejection fraction, or HFrEF, to cover patients across the full spectrum of left ventricular ejection fraction, or LVEF, including HF with mildly reduced and preserved ejection fraction, or HFmrEF and HFpEF, the company announced.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’